Which has better earnings & valuation, NEO or HNGE?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 3.52 -$108.03M -$0.40 N/A Hinge Health $587.86M 13.05 -$528.26M $1.28 74.31

Is NEO or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% Hinge Health 15.15% 51.60% 14.16%

Does the media refer more to NEO or HNGE?

In the previous week, Hinge Health had 8 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Hinge Health and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Hinge Health's score of 0.42 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CHE or NEO?

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.60 $265.24M $19.91 25.27 NeoGenomics $727.33M 3.52 -$108.03M -$0.40 N/A

Is CHE or NEO more profitable?

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% NeoGenomics -6.77% -1.99% -1.21%

Does the media prefer CHE or NEO?

In the previous week, Chemed had 2 more articles in the media than NeoGenomics. MarketBeat recorded 7 mentions for Chemed and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Chemed's score of 0.33 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NEO or HIMS?

In the previous week, Hims & Hers Health had 46 more articles in the media than NeoGenomics. MarketBeat recorded 51 mentions for Hims & Hers Health and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Hims & Hers Health's score of 0.11 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 7 Very Positive mention(s) 4 Positive mention(s) 35 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RDNT or NEO?

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.93 -$18.65M -$0.27 N/A NeoGenomics $727.33M 3.52 -$108.03M -$0.40 N/A

Is RDNT or NEO more profitable?

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% NeoGenomics -6.77% -1.99% -1.21%

Does the media prefer RDNT or NEO?

In the previous week, RadNet and RadNet both had 5 articles in the media. NeoGenomics' average media sentiment score of 0.77 beat RadNet's score of 0.50 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFST or NEO?

In the previous week, NeoGenomics had 2 more articles in the media than LifeStance Health Group. MarketBeat recorded 5 mentions for NeoGenomics and 3 mentions for LifeStance Health Group. NeoGenomics' average media sentiment score of 0.77 beat LifeStance Health Group's score of 0.67 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeoGenomics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeoGenomics (NEO) Competitors

$19.91 +0.02 (+0.10%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.14 +0.23 (+1.16%)

As of 09/18/2026 07:30 PM Eastern

Compare

NEO vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy NeoGenomics stock or one of its competitors? NeoGenomics's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 18.9% of Hinge Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.52	-$108.03M	-$0.40	N/A
Hinge Health	$587.86M	13.05	-$528.26M	$1.28	74.31

In the previous week, Hinge Health had 8 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Hinge Health and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Hinge Health's score of 0.42 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hinge Health	15.15%	51.60%	14.16%

NeoGenomics currently has a consensus target price of $17.67, suggesting a potential downside of 11.27%. Hinge Health has a consensus target price of $101.93, suggesting a potential upside of 7.17%. Given Hinge Health's stronger consensus rating and higher probable upside, analysts clearly believe Hinge Health is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Hinge Health beats NeoGenomics on 11 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Chemed?

Chemed (NYSE:CHE) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.60	$265.24M	$19.91	25.27
NeoGenomics	$727.33M	3.52	-$108.03M	-$0.40	N/A

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
NeoGenomics	-6.77%	-1.99%	-1.21%

Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Chemed presently has a consensus price target of $530.75, indicating a potential upside of 5.49%. NeoGenomics has a consensus price target of $17.67, indicating a potential downside of 11.27%. Given Chemed's higher probable upside, equities research analysts plainly believe Chemed is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

95.9% of Chemed shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 1.1% of NeoGenomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Chemed had 2 more articles in the media than NeoGenomics. MarketBeat recorded 7 mentions for Chemed and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Chemed's score of 0.33 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats NeoGenomics on 10 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Hims & Hers Health?

NeoGenomics (NASDAQ:NEO) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

NeoGenomics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Hims & Hers Health has a net margin of -5.51% compared to NeoGenomics' net margin of -6.77%. NeoGenomics' return on equity of -1.99% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

NeoGenomics currently has a consensus price target of $17.67, suggesting a potential downside of 11.27%. Hims & Hers Health has a consensus price target of $32.43, suggesting a potential upside of 15.82%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Hims & Hers Health had 46 more articles in the media than NeoGenomics. MarketBeat recorded 51 mentions for Hims & Hers Health and 5 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.77 beat Hims & Hers Health's score of 0.11 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	7 Very Positive mention(s)	4 Positive mention(s)	35 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hims & Hers Health has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.52	-$108.03M	-$0.40	N/A
Hims & Hers Health	$2.35B	2.78	$128.37M	-$0.63	N/A

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Hims & Hers Health beats NeoGenomics on 9 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to RadNet?

RadNet (NASDAQ:RDNT) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

RadNet has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
NeoGenomics	-6.77%	-1.99%	-1.21%

In the previous week, RadNet and RadNet both had 5 articles in the media. NeoGenomics' average media sentiment score of 0.77 beat RadNet's score of 0.50 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.93	-$18.65M	-$0.27	N/A
NeoGenomics	$727.33M	3.52	-$108.03M	-$0.40	N/A

77.9% of RadNet shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 5.1% of RadNet shares are held by company insiders. Comparatively, 1.1% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RadNet currently has a consensus target price of $90.00, suggesting a potential upside of 18.42%. NeoGenomics has a consensus target price of $17.67, suggesting a potential downside of 11.27%. Given RadNet's stronger consensus rating and higher possible upside, equities analysts plainly believe RadNet is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

RadNet beats NeoGenomics on 10 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

LifeStance Health Group has a net margin of 3.19% compared to NeoGenomics' net margin of -6.77%. LifeStance Health Group's return on equity of 3.39% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	3.19%	3.39%	2.33%
NeoGenomics	-6.77%	-1.99%	-1.21%

In the previous week, NeoGenomics had 2 more articles in the media than LifeStance Health Group. MarketBeat recorded 5 mentions for NeoGenomics and 3 mentions for LifeStance Health Group. NeoGenomics' average media sentiment score of 0.77 beat LifeStance Health Group's score of 0.67 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeoGenomics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

LifeStance Health Group presently has a consensus price target of $12.88, indicating a potential upside of 2.43%. NeoGenomics has a consensus price target of $17.67, indicating a potential downside of 11.27%. Given LifeStance Health Group's stronger consensus rating and higher probable upside, equities analysts clearly believe LifeStance Health Group is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

85.5% of LifeStance Health Group shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 3.5% of LifeStance Health Group shares are owned by company insiders. Comparatively, 1.1% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LifeStance Health Group has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	3.37	$9.66M	$0.13	96.69
NeoGenomics	$727.33M	3.52	-$108.03M	-$0.40	N/A

Summary

LifeStance Health Group beats NeoGenomics on 10 of the 15 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.56B	$9.75B	$7.24B	$13.21B
Dividend Yield	N/A	2.62%	2.57%	12.80%
P/E Ratio	-49.78	34.09	275.49	25.40
Price / Sales	3.52	4.95	639.55	86.82
Price / Cash	59.43	121.76	76.25	51.42
Price / Book	3.08	5.30	10.46	6.33
Net Income	-$108.03M	$313.45M	$3.49B	$358.33M
7 Day Performance	14.95%	1.65%	0.59%	1.12%
1 Month Performance	20.45%	-0.85%	-1.74%	-2.39%
1 Year Performance	133.69%	16.30%	18.13%	5.35%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	1.8233 of 5 stars	$19.91 +0.1%	$17.67 -11.3%	+133.7%	$2.56B	$727.33M	N/A	2,500	High Trading Volume
HNGE Hinge Health	3.1493 of 5 stars	$94.45 +6.6%	$101.93 +7.9%	+66.7%	$7.15B	$587.86M	73.79	1,437	Insider Trade
CHE Chemed	4.0518 of 5 stars	$514.33 -0.3%	$530.75 +3.2%	+11.3%	$6.74B	$2.60B	25.83	15,811	News Coverage Analyst Downgrade
HIMS Hims & Hers Health	2.591 of 5 stars	$28.77 +4.6%	$32.43 +12.7%	-51.5%	$6.42B	$2.58B	N/A	2,442	Trending News Insider Trade Gap Up
RDNT RadNet	2.7462 of 5 stars	$75.49 flat	$90.00 +19.2%	-0.6%	$5.94B	$2.27B	N/A	11,264	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. HNGE, CHE, HIMS, RDNT, and LFST

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to Chemed?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Summary

How does NeoGenomics compare to RadNet?

Summary

How does NeoGenomics compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. HNGE, CHE, HIMS, RDNT, and LFST

How does NeoGenomics compare to Hinge Health?

Do institutionals & insiders have more ownership in NEO or HNGE?

Which has better earnings & valuation, NEO or HNGE?

Does the media refer more to NEO or HNGE?

Which has more risk and volatility, NEO or HNGE?

Is NEO or HNGE more profitable?

Do analysts rate NEO or HNGE?

Summary

How does NeoGenomics compare to Chemed?

Which has preferable earnings and valuation, CHE or NEO?

Is CHE or NEO more profitable?

Which has more risk and volatility, CHE or NEO?

Do analysts prefer CHE or NEO?

Do institutionals and insiders believe in CHE or NEO?

Does the media prefer CHE or NEO?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Which has more volatility and risk, NEO or HIMS?

Is NEO or HIMS more profitable?

Do analysts rate NEO or HIMS?

Does the media favor NEO or HIMS?

Which has preferable earnings & valuation, NEO or HIMS?

Do insiders and institutionals hold more shares of NEO or HIMS?

Summary

How does NeoGenomics compare to RadNet?

Which has more volatility and risk, RDNT or NEO?

Is RDNT or NEO more profitable?

Does the media prefer RDNT or NEO?

Which has better valuation and earnings, RDNT or NEO?

Do institutionals & insiders have more ownership in RDNT or NEO?

Do analysts rate RDNT or NEO?

Summary

How does NeoGenomics compare to LifeStance Health Group?

Is LFST or NEO more profitable?

Does the media refer more to LFST or NEO?

Which has more risk and volatility, LFST or NEO?

Do analysts rate LFST or NEO?

Do institutionals & insiders have more ownership in LFST or NEO?

Which has better earnings & valuation, LFST or NEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools